Alternatives for adopting policies centered on access to medicines;Alternativas para la adopción de políticas centradas en el acceso a medicamentos

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 32, Issue 6, 2012, Pages 457-463

  Tobar, Federico ^a   Drake, Ignacio ^b   Martich, Evangelina ^c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Ministry of Health   (Argentina)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Drug price; Drugs; Financing; Generic; Health; Health investments; Latin America

Indexed keywords

DECISION MAKING; DRUG; FINANCIAL PROVISION; HEALTH POLICY; STANDARD (REGULATION);

LATIN AMERICA;

EID: 84874858757     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/s1020-49892012001400010     Document Type: Review

References (30)

1. Organización Panamericana de la Salud. Guía para la implementación de estrategias de medicamentos genéricos en los países de América Latina y el Caribe como mecanismo para mejorar el acceso a medicamentos; 2011. Disponible en: http://apps.who.int/medicinedocs/ documents/s19196es/s19196es.pdf Acceso el 8 de noviembre de 2012.
2. Tobar F. Estrategias económicas y financiamiento del medicamento. En: Bermudez J, Oliveira MA, Esher A, eds. Acceso a Medicamentos: Derecho fundamental, papel del Estado. Río de Janeiro: ENSP; 2004.
3. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M, Medical Technology Research Group-LSE Health, et al. Differences in costs of and access to pharmaceutical products in the EU. Brussels: European Parliament; 2011. P. 92.
4. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 european countries-an overview. Generics and Biosimilars Initiative Journal. 2012;1(2):93-100.
5. Puig-Junoy J. Políticas de fomento de la competencia en precios en el mercado de genéricos: lecciones de la experiencia europea. Gac Sanit. 2010;24(3):193-9.
6. Nguyen A, Kaplan WA, Laing R. Policy options for promoting the use of generic medicines in developing and transitional countries: a review paper. Geneva: World Health Organization; 2008.
7. Dylst P, Simoens S. Generic Medicine Pricing Policies in Europe: Current Status and Impact. Pharmaceuticals. 2010;3(3):471-81.
8. Pharmaceutical Pricing and Reimbursement Information (PPRI). Portugal Pharma Profile Vienna: European Commission, Health and Consumer Protection Directorate-General and the Austrian Ministry of Health, Family and Youth; 2008.
9. Garcia R. España prepara un nuevo paquete de medidas de contención del gasto en medicamentos, 2011. Disponible en: http://www.correofarmaceutico.com/2011/07/04/al-dia/profesion/ el-gobierno-prepara-mas-medidasde-contencion-para-el-interterritorial Acceso el 16 de noviembre de 2012.
10. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 2000;54(2):87-123.
11. Vogler S, Habl C, Leopold C, Rosian-Schikuta I, Joncheere Kd, Thomsen TL. Pharmaceutical Pricing and Reimbursement Information (PPRI) Report. Vienna: European Commission, Health and Consumer Protection Directorate-General and Austrian Federal Ministry of Health, Family And Youth; 2008.
12. Danzon PM, Ketcham JD. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand. Cambridge: National Bureau of Economic Research; 2004.
13. Yadav P. Differential Pricing for Pharmaceuticals. Review of current knowledge, new findings and ideas for action. Zaragoza: MIT-Zaragoza International Logistics Program; 2010.
14. Brekke KR, Königbauer I, Straume OR. Reference Pricing of Pharmaceuticals. J Health Econ. 2005;26(3):613-42.
15. Espín J, Rovira J. Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe. Brussels: DG Enterprise and Industry of the European Commission; 2007.
16. Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2010;12(3):263-71.
17. Pharmaceutical Pricing and Reimbursement Information (PPRI). France Pharma Profile. Vienna: European Commission, Health and Consumer Protection Direc-torate-General and the Austrian Ministry of Health, Family and Youth; 2008.
18. Pharmaceutical Pricing and Reimbursement Information (PPRI). Germany Pharma Profile. Vienna: European Commission, Health and Consumer Protection Directorate-General and the Austrian Ministry of Health, Family and Youth; 2008.
19. Pharmaceutical Pricing and Reimbursement Information (PPRI). Italy Pharma Profile. Vienna: European Commission, Health and Consumer Protection Directorate-General and the Austrian Ministry of Health, Family and Youth; 2007.
20. Pharmaceutical Pricing and Reimbursement Information (PPRI). Sweden Pharma Profile. Vienna: European Commission, Health and Consumer Protection Directorate-General and the Austrian Ministry of Health, Family and Youth; 2007.
21. Birkett DJ, Mitchell AS, McManus P. A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia. Health Aff (Millwood). 2011;20(3):104-14.
22. Tobar F, Moretti C. Regulación económica de medicamentos en América Latina. Isalud. 2009;4(17):37-44.
23. Seiter A. A practical approach to pharmaceutical policy. Washington D.C: The World Bank; 2010.
24. Homedes N, Linares RL, Ugalde A. Generic Drug Policies in Latin America. Texas: World Bank; 2005.
25. Tobar F. Economía de los medicamentos genéricos en América Latina. Rev Panam Salud Publica. 2008;23(1):59-67.
26. Tobar F. Modelos de regulación económica de medicamentos en América Latina, 2008. Disponible en: http://www.federicotobar.com.ar/nf- pdf2/Regulacion.pdf Acceso el 16 de noviembre de 2012.
27. Tobar F, Sánchez D. El impacto de las políticas de medicamentos genéricos sobre el mercado de medicamentos en tres países del MERCOSUR. Montevideo: Fundación Carolina; 2005.
28. Maierovitch C. Política Vigente para Regulamentação de Medicamentos no Brasil. Brasilia: ANVISA; 2004.
29. Luiza VL, Castro CO, Marín N. Estudio de vigilancia de políticas farmacéuticas, Nivel 1 (estructura y procesos) realizado en países de Latinoamérica y el Caribe en 2003. Río de Janeiro: NAF/ENSP/FIOCRUZ/OPS/WDC; 2006.
30. Bermúdez J, Possas C. Análisis crítico de la política de medicamentos en el Brasil. Boletín de la Oficina Sanitaria Panamericana. 1995;119:270-7.